PICO negative pressure
wound dressings for closed
surgical incisions

Medical technologies guidance
Published: 9 May 2019
Last updated: 6 August 2019

www.nice.org.uk/guidance/mtg43
Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.
Contents

1 Recommendations .................................................................................................................. 4

2 The technology .................................................................................................................... 5

3 Evidence ................................................................................................................................ 7
   Clinical evidence ...................................................................................................................... 7
   Cost evidence .......................................................................................................................... 10

4 Committee discussion ......................................................................................................... 12
   Clinical-effectiveness overview ............................................................................................ 12
   Side effects and adverse events ............................................................................................ 13
   Relevance to the NHS ........................................................................................................... 14
   NHS considerations .............................................................................................................. 15
   Cost modelling overview ...................................................................................................... 15
   Main cost drivers .................................................................................................................... 16
   Cost savings ............................................................................................................................ 17

5 Committee members and NICE project team .................................................................... 18
   Committee members .............................................................................................................. 18
   NICE project team ................................................................................................................ 18

Update information .................................................................................................................. 19
1 Recommendations

1.1 Evidence supports the case for adopting PICO negative pressure wound dressings for closed surgical incisions in the NHS. They are associated with fewer surgical site infections and seromas compared with standard wound dressings.

1.2 PICO negative pressure wound dressings should be considered as an option for closed surgical incisions in people who are at high risk of developing surgical site infections. Risk factors for surgical site infections are described in section 4.2.

1.3 Cost modelling suggests that PICO negative pressure wound dressings provide extra clinical benefits at a similar overall cost compared with standard wound dressings.

Why the committee made these recommendations

PICO negative pressure wound dressings are designed to allow an even distribution of negative pressure on the surface of a closed surgical incision. The system is also designed to be portable. Clinical evidence shows that using PICO dressings for closed surgical incisions can lead to fewer surgical site infections. Evidence also shows that using PICO dressings reduces the rate of seromas compared with standard wound dressings. Cost analyses suggest that using PICO dressings will not add to the overall costs of treatment.
## 2 The technology

<table>
<thead>
<tr>
<th>Technology</th>
<th>PICO is a canister-free, single-use, negative pressure wound therapy system consisting of a sterile pump and multi-layered adhesive dressings. Each dressing has 4 layers: a silicone adhesive wound contact layer, which is designed to minimise pain and damage during peel-back and to reduce lateral tension; an airlock layer for even distribution of pressure; an absorbent layer to remove exudate and bacteria from the wound; and a top film layer, which acts as a physical barrier and allows moisture to evaporate. The pump is operated by 2 AA batteries and delivers a continuous negative pressure of 80 mmHg to a sealed wound. Once activated, using a push button, the battery drives the pump for up to 7 days and LEDs provide alerts for low-battery status and pressure leaks. Standard PICO dressings come in 8 sizes: 10×20 cm, 10×30 cm, 10×40 cm, 15×15 cm, 15×20 cm, 15×30 cm, 20×20 cm and 25×25 cm. Multisite PICO dressings come in 2 sizes: small (15×20 cm) and large (20×25 cm). The latest version of the technology is the PICO7 system. This differs from the version of PICO notified to NICE by having an improved pump to minimise leakage and an integrated belt clip to allow for easier transport. The PICO7 pump contains a magnet and it should be positioned at least 10 cm (4 inches) away from other medical devices that could be affected by magnetic interference.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovative aspects</td>
<td>PICO differs from conventional negative pressure wound dressings in that it:</td>
</tr>
<tr>
<td></td>
<td>• has no separate canister</td>
</tr>
<tr>
<td></td>
<td>• is portable and disposable</td>
</tr>
<tr>
<td></td>
<td>• has a proprietary dressing layer that is designed to allow even distribution of negative pressure across the incision and zone of injury.</td>
</tr>
</tbody>
</table>
### Intended use

PICO is intended for surgical incisions with low or moderate levels of exudate. This guidance focuses on the use of PICO dressings for closed surgical incisions. PICO dressings can be applied by healthcare professionals including surgeons and tissue viability nurses for people in a range of care settings. Training is needed to place the dressings correctly (see section 4.8).

### Costs

Standard PICO dressings are available in 8 different sizes. Each pack includes a single-use pump and 2 dressings. The list prices for PICO dressings range from £127.06 to £145.68 (including VAT).

For more details, see the [website for PICO dressings](https://www.nice.org.uk/terms-and-conditions#notice-of-rights).
3 Evidence

Clinical evidence

Relevant evidence comes from 31 studies, 15 of which are randomised controlled trials

3.1 Of the 31 studies that provided evidence relevant to the decision problem, 15 were randomised controlled trials and 16 were non-randomised comparative observational studies. The 15 randomised controlled trials were done in secondary or tertiary care and were based on preventing surgical site complications in people with closed surgical incisions who were at high risk of complications after surgery. One was done in the UK. For full details of the clinical evidence, see section 3 of the assessment report.

Randomised controlled trial evidence shows fewer surgical site infections with PICO dressings compared with standard wound dressings

3.2 Of the 15 randomised controlled trials, 8 compared PICO dressings with standard wound dressings in people with closed surgical incisions in Australia, Poland, the UK, Ireland, Japan, Denmark and the US (Chayboyer et al. 2014, Gillespie et al. 2015, Witt-Najchrazak et al. 2015, Karlakki et al. 2016, O’Leary et al. 2016, Uchino et al. 2016, Hyldig et al. 2018 and Galiano et al. 2018 respectively). The studies included a wide range of different types of surgery. The external assessment centre (EAC) considered these studies to have acceptable internal and external validity and to provide relevant evidence on the effectiveness of PICO dressings. Pooled effect estimates from a random-effects meta-analysis of the 8 studies showed a significant reduction in surgical site infection rates in favour of PICO dressings (n=1,804, odds ratio [OR] 0.51, 95% confidence interval [CI] 0.3 to 0.82; p=0.006).
Results from observational studies support the randomised controlled trial evidence

3.3 Of the 16 non-randomised comparative observational studies, 10 compared the rates of surgical site infection using PICO dressings with standard wound dressings in people with closed surgical incisions (Adogwa et al. 2014, Matsumoto et al. 2014, Pellino et al. 2014, Pellino et al. 2014b, Selvaggi et al. 2014, Hickson et al. 2015, Fleming et al. 2017, Tan et al. 2017, van der Valk et al. 2017 and Dingemans et al. 2018). The studies included a wide range of different types of surgery. The EAC considered the included observational studies to have acceptable levels of both internal and external validity, and concluded that the evidence was relevant to the decision problem. Pooled effect estimates from a random-effects meta-analysis of the 10 studies showed a significant reduction in surgical site infection rates in favour of PICO dressings (n=2,669, OR 0.27, 95% CI 0.14 to 0.53; p=0.001). However, the EAC noted that the observational studies may overestimate the clinical benefits of PICO dressings because of potential selection and publication bias.

Pooled analyses show a reduction in the rate of seromas with PICO dressings

3.4 Two of the randomised controlled trials and 5 of the observational studies also reported rates of seromas in people with closed surgical incisions. Pooled effect estimates from a random-effects meta-analysis of these 7 studies showed a significant reduction in the incidence of seromas in favour of PICO dressings in a range of different types of surgery (n=771, OR 0.19, 95% CI 0.08 to 0.47; p=0.0003). The EAC noted that this reduction in seroma rates was mainly driven by the observational study results.

Reductions in surgical site infections with PICO dressings vary across different types of surgery

3.5 The included studies considered the use of PICO dressings for 6 different types of surgery:
- orthopaedic surgery (2 randomised controlled trials and 3 observational studies, n=607)
- colorectal surgery (1 randomised controlled trial and 4 observational studies, n=209)
- obstetric surgery (2 randomised controlled trials and 1 observational study, n=2,911)
- plastic/breast surgery (1 randomised controlled trial and 1 observational study, n=420)
- vascular surgery (2 observational studies, n=193)
- cardiothoracic surgery (1 randomised controlled trial, n=80).

Analyses by surgery type showed that reductions in the rate of surgical site infection rates with PICO varied across different types of surgery: the reductions were only significant in obstetric surgery (OR 0.48, 95% CI 0.30 to 0.76; p=0.002) and orthopaedic surgery (OR 0.45, 95% CI 0.22 to 0.91; p=0.03).

There are limitations in the evidence but it is relevant to the decision problem

3.6 The EAC noted the clinical and statistical heterogeneity of the studies that were included in the meta-analyses. There was wide variation in the risk characteristics of the populations, the definition of surgical site infections, how long the dressing was in place, and the length and frequency of follow up. The analyses based on surgery type also included relatively few studies. Nonetheless, the random-effects meta-analyses included a relatively large number of study populations and the EAC concluded that the results were relevant to the decision problem.

PICO dressings may be linked to increased risk of skin blister and maceration in some people

3.7 One randomised controlled trial (Karlakki et al. 2016) reported a higher overall rate of blisters in people who had PICO dressings compared with
those who had standard wound dressings (11% compared with 1%). The rate of blisters differed considerably between the 3 surgeons who took part in the study. For full details of the adverse events, see section 3.7 of the assessment report.

Cost evidence

The company's cost model shows that PICO dressings are cost saving in people with closed surgical incisions

3.8 The company's base-case model showed that 90 days after surgery, PICO dressings are cost saving by around £101 per person compared with standard wound dressings.

The EAC's changes to the cost model more accurately reflect the costs and consequences to the NHS

3.9 The EAC considered that the structure of the company's cost model was adequate for decision making. However, it identified some limitations in the model parameters and made changes to better reflect potential resource use in the NHS. Specifically, the EAC:

- applied baseline incidence rates and the cost of surgical site infections from a UK data source (Jenks et al. 2014)
- calculated the mean cost of surgical site infections by dividing the cost by the number of infections
- updated the number of PICO and comparator dressings used
- used clinical-effectiveness estimates based on the pooled treatment effect from the meta-analysis of the randomised controlled trials.

For full details of the changes and results, see section 4 of the assessment report.

The EAC's updated analysis shows that PICO dressings are cost
neutral overall but this varies by type of surgery

3.10 With the EAC's changes, the base-case model showed that 90 days after surgery, PICO dressings are cost saving by around £6 per person compared with standard wound dressings. The main drivers of these savings were the cost of PICO, the likelihood of a surgical site infection, the cost of a surgical site infection and the effectiveness of PICO in reducing the incidence of surgical site infections. The analyses by surgery type showed that PICO was cost saving for colorectal, cardiothoracic and vascular surgery, but was not cost saving for orthopaedic, obstetric and plastic/breast surgery. For full details of the cost evidence, see section 4 of the assessment report.
4 Committee discussion

Clinical-effectiveness overview

PICO dressings are associated with lower rates of surgical site infections in people with closed surgical incisions compared with standard dressings

4.1 The committee noted considerable evidence to show the effectiveness of PICO in reducing rates of surgical site infections (18 studies) and seromas (7 studies). The company did meta-analyses using a fixed-effect model, whereas the external assessment centre (EAC) used a random-effects model. The committee considered that the EAC's approach was more appropriate because of the wide variation in the study populations, interventions and the definitions of surgical site infections. The committee concluded that there was convincing evidence that using PICO dressings reduces surgical site infections and seromas in people with closed surgical incisions. The committee considered that there was less certainty about how PICO dressings affect other surgical site complications (such as wound dehiscence, haematoma, delayed healing or excessive scarring) because of the small number of studies in the analyses.

Careful patient selection is important and should be informed by NICE guidance

4.2 The experts advised that careful patient selection was important when using PICO dressings. The committee noted that the included studies only recruited people who were considered to be at high risk of developing surgical site complications, but that many of the studies did not explicitly state the definition of high risk. The experts advised that there were a number of factors associated with an increased risk of surgical site complications, including age, obesity, cigarette smoking and diabetes. There are also several surgical situations that increase the risk,
such as repeat operations and the need for emergency surgery. The committee noted that a NICE evidence review\textsuperscript{[1]} identified the main risk factors for surgical site infections as age, underlying illness, obesity, smoking, wound classification, and site and complexity of procedure. It concluded that healthcare professionals should take these factors into account when considering whether to use PICO dressings.

**PICO dressings should be used for closed surgical incisions which are unlikely to need multiple dressing changes**

4.3 The committee noted that PICO is intended for closed surgical incisions in which the amount of exudate was anticipated to be low or moderate. The clinical experts advised that PICO dressings should be used for closed surgical incisions that are unlikely to need multiple dressing changes. Large amounts of exudate may lead to multiple dressing changes being needed, so PICO dressings should not be used for these types of wounds.

**Benefits of PICO dressings vary by type of surgery**

4.4 The committee noted that the published evidence included the use of PICO dressings in 6 different types of surgery, and that the meta-analysis identified a statistically significant reduction in the risk of surgical site infections when it was used in orthopaedic and obstetric surgery. The committee concluded that the type of surgery was an important factor in selecting people for PICO dressings, and that it should be considered in the overall risk assessment for post-operative complications. However, the committee considered that the evidence was too limited to make recommendations on the use of PICO dressings by surgery type.

**Side effects and adverse events**

**Adverse events are uncommon but some people may develop skin blisters and maceration with PICO dressings**

4.5 The committee noted that adverse events were rare in the studies but
that skin blisters and maceration may occur when using PICO dressings. A clinical expert advised that skin blisters may develop because of skin tension, which is likely to be the result of the dressing being stretched over the wound. This was corroborated by the results of 1 study, in which the highest incidence of skin blisters was in people whose dressings were applied by trainee staff.

Pump failure may incur additional costs but this is rare

4.6 The company stated that there had been around 147 reported cases of the PICO pump failing since its launch in 2007. The committee considered that pump failure would incur additional costs, including application of additional dressings and pump replacement, but it acknowledged that the reported rates of pump failure were very low.

Relevance to the NHS

The evidence for PICO dressings is broadly generalisable to the NHS

4.7 The committee noted that only a small number of the studies included NHS settings; for example, only 1 of the randomised controlled trials was done in the UK. However, 9 of the studies included in the meta-analyses were done in European countries including Ireland, Italy, the Netherlands, Denmark and Poland. A clinical expert stated that PICO dressings are widely used across Europe and that both population demographics and the fundamentals of wound therapy were likely to be similar across Europe. The committee concluded that the evidence for PICO dressings was broadly generalisable to the NHS.

The evidence is generalisable to the PICO7 system

4.8 The committee noted that since the technology was notified to NICE, newer versions of PICO dressings have been developed. The latest version available to the NHS is the PICO7 system. The company confirmed that the PICO7 has an improved pump design and belt clip but that the functional mechanism of the dressings remains the same. The
committee considered that the evidence on which it evaluated PICO dressings was generalisable to the PICO7 system.

NHS considerations

Some training is needed in how to apply PICO dressings

4.9 The clinical experts advised that training was an important consideration in the use of PICO dressings. Maintaining a seal is integral to the continued effectiveness of negative pressure, but in creating the seal it is important to ensure that the skin is not placed under excessive tension. The experts also described certain situations in which applying the dressing was awkward (such as on the lower abdomen after a caesarean section or over bony protrusions, especially if there is excessive moisture). The experts also stated that training is important for healthcare staff who provide post-operative care both in hospital and in the community. They emphasised that a lack of knowledge may lead to dressings being removed too early, or to unnecessary dressing changes that are likely to negatively affect clinical outcomes and costs. The committee concluded that training was important in realising the benefits of PICO dressings.

Cost modelling overview

The EAC's updated model is more appropriate for decision making

4.10 The committee noted the EAC’s changes to the company’s cost model (see section 3.9) and agreed that the updated model better reflected cost and resource use in the NHS. The committee considered the numbers of PICO dressings and standard dressings that were likely to be needed per person, and the importance of length of stay in hospital in determining cost calculations. It noted that the instructions for use suggest that 1 PICO kit (1 pump and 2 dressings) will last for up to 7 days after surgery. However, the clinical experts indicated that the number of dressings used and the length of stay vary widely depending on the type
of surgery. The EAC explained that its calculations were based on the use of 1.09 PICO dressings per person with an average of 5.3 days' stay in hospital. It also estimated the number of PICO dressings used by surgery type; for example, it estimated 1.81 PICO dressings used for colorectal surgery and 1.58 used for vascular surgery. The committee concluded that although it agreed with the EAC's approach to cost modelling, there were uncertainties because of the differences in the populations considered.

Main cost drivers

It is likely that the additional cost of PICO dressings will be offset by a reduction in surgical site infections

4.11 The committee noted how the rate and cost of surgical site infections affected the outcomes of the cost modelling. Having seen convincing evidence to support a reduction in the rate of surgical site infections with PICO dressings, the committee concluded it was plausible that the additional cost of PICO dressings compared with standard wound dressings would be offset by a reduction in the overall costs associated with treating surgical site infections.

The model is most sensitive to the purchase cost and effectiveness of PICO dressings

4.12 The EAC did sensitivity analyses, which showed that the cost model was most sensitive to the purchase cost of PICO dressings and their effectiveness in reducing surgical site infections.

The model does not include staff costs for applying dressings but these are negligible

4.13 The committee noted that neither the company's original model nor the EAC's updated model included staff costs associated with applying PICO and standard wound dressings. Although applying a PICO dressing could take an additional 1 or 2 minutes compared with applying a standard
wound dressing, a clinical expert noted that for appropriately trained staff any additional time was negligible.

Cost savings

PICO dressings provide extra benefits at no additional cost to the NHS

4.14 The committee recalled the EAC's updated cost model, which suggested that PICO dressings are cost saving by around £6 per person (although the cost saving may vary by type of surgery). Overall, the committee concluded that PICO dressings are likely to provide extra clinical benefits at a similar overall cost compared with standard wound dressings.

[1] The committee considered an evidence review done for NICE's 2008 guideline on preventing and treating surgical site infections (section 3).
5 Committee members and NICE project team

Committee members

This topic was considered by the medical technology advisory committee which is a standing advisory committee of NICE.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

The minutes of each committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

NICE project team

Each medical technologies guidance topic is assigned to a team consisting of 1 or more technical analysts (who act as technical leads for the topic), a technical adviser and a project manager.

YingYing Wang
Technical analyst

Lizzy Latimer
Technical adviser

Jae Long
Project manager
Update information

August 2019: Section 2 amended to add details about magnetic interference from the PICO7 pump.

ISBN: 978-1-4731-3418-8

Accreditation

NICE accredited

www.nice.org.uk/accreditation